Ascendiant Capital Markets Predicts Pro-Dex Q1 Earnings

Pro-Dex, Inc. (NASDAQ:PDEX) – Stock analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for Pro-Dex in a research note issued on Monday, May 11th. Ascendiant Capital Markets analyst E. Woo expects that the medical instruments supplier will post earnings of $0.66 per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $70.00 target price on the stock. Ascendiant Capital Markets also issued estimates for Pro-Dex’s Q2 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.74 EPS, Q4 2027 earnings at $0.70 EPS and FY2027 earnings at $2.78 EPS.

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pro-Dex in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.

Pro-Dex Stock Down 0.0%

Shares of NASDAQ PDEX opened at $56.50 on Wednesday. Pro-Dex has a 1 year low of $23.47 and a 1 year high of $61.62. The firm has a market cap of $180.24 million, a price-to-earnings ratio of 15.61 and a beta of -0.12. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.14 and a current ratio of 3.67. The stock’s 50-day simple moving average is $50.45 and its 200-day simple moving average is $42.47.

Pro-Dex (NASDAQ:PDEX) last announced its earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.58. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%.The business had revenue of $19.95 million for the quarter, compared to analyst estimates of $17.90 million.

Hedge Funds Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Dempsey Capital Management LLC boosted its stake in Pro-Dex by 6.2% in the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock valued at $286,000 after acquiring an additional 339 shares during the period. Quadrature Capital Ltd acquired a new position in Pro-Dex in the fourth quarter valued at approximately $220,000. Osaic Holdings Inc. boosted its stake in Pro-Dex by 44.8% in the fourth quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier’s stock valued at $440,000 after acquiring an additional 3,540 shares during the period. Punch & Associates Investment Management Inc. boosted its stake in Pro-Dex by 23.4% in the fourth quarter. Punch & Associates Investment Management Inc. now owns 60,000 shares of the medical instruments supplier’s stock valued at $2,309,000 after acquiring an additional 11,392 shares during the period. Finally, Royal Bank of Canada boosted its stake in Pro-Dex by 603.4% in the fourth quarter. Royal Bank of Canada now owns 4,080 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 3,500 shares during the period. 15.28% of the stock is currently owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.